The National Institutes of Health (NIH) is a leading biomedical research facility in the United States, operating under the Department of Health and Human Services. Established in 1887 and based in Bethesda, Maryland, NIH is the primary agency responsible for biomedical and health-related research in the country. It comprises 27 separate institutes and centers, each focusing on different disciplines within biomedical science. NIH conducts its own scientific research through the Intramural Research Program and provides significant funding for research at external institutions via the Extramural Research Program. With a workforce that includes 1,200 principal investigators and over 4,000 postdoctoral fellows, NIH has been instrumental in major medical breakthroughs, such as the development of vaccines for hepatitis and human papillomavirus, as well as the discovery of treatments for various health conditions. As the world's largest source of medical research funding, NIH continues to advance scientific knowledge and contribute to public health improvements.
InVivo Biosystems specializes in utilizing non-mammalian model organisms for biological and biomedical research. The company has developed a proprietary transgenic platform that allows for the genetic modification of simple microscopic animals, such as C. elegans and zebrafish, to serve as human proxies in disease research and drug discovery. This innovative approach provides researchers with valuable insights into genetic mutations and human health. By offering custom genome-edited models, InVivo Biosystems supports pharmaceutical, nutraceutical, and biotechnology companies, as well as academic institutions, in accelerating their research and drug development initiatives. The company aims to make research more affordable and accessible, ultimately contributing to the exploration of treatments for significant health challenges, including Alzheimer's disease, epilepsy, and cancer.
Invizyne
Grant in 2025
Invizyne specializes in the design of enzymes and the development of cell-free enzymatic pathways that operate independently of living cells. This innovative approach addresses many challenges associated with traditional biomanufacturing methods, which often rely on cell-based systems. By utilizing its proprietary platform, SimplePath, Invizyne aims to transform natural and renewable resources into a variety of valuable chemicals, including pharmaceuticals, fuels, materials, and food additives. The SimplePath system is designed as a modular cascade, allowing for efficient multi-step enzymatic processes. This positions Invizyne as a promising alternative to conventional chemical production methods, such as chemical synthesis and natural extraction, thus redefining the landscape of biomanufacturing.
GreenMark Biomedical
Grant in 2025
GreenMark Biomedical Inc. is a healthcare company focused on developing minimally invasive technologies utilizing biopolymer nanoparticles derived from natural starch. Founded in 2016 and based in East Lansing, Michigan, with a laboratory in Ann Arbor, the company aims to enhance diagnostic and treatment capabilities in dentistry and oncology. GreenMark offers a mouth rinse product that highlights cavities and early-stage lesions, allowing dentists to accurately assess dental issues using standard dental curing lamps. Additionally, the company is working on medical applications that target anti-cancer drug delivery, facilitating site-specific treatments. Through its innovative approach, GreenMark Biomedical seeks to provide effective health-based solutions that improve patient care.
Sonomotion
Grant in 2025
SonoMotion Inc. is a medical device company focused on developing non-invasive solutions for kidney stone disease. Founded in 2012 and based in San Mateo, California, the company offers innovative products such as Break Wave, which safely fragments large kidney stones, and Stone Clear, which aids in clearing the resulting stone fragments within 15 minutes in an office setting, without the need for general anesthesia or X-ray radiation. SonoMotion is actively involved in advancing its technology, with a stone repositioning solution currently undergoing clinical trials and a second-generation stone-breaking technology in development. The company's mission is to provide effective and cost-efficient treatments for kidney stone patients.
LUCID DIAGNOSTICS
Grant in 2025
Lucid Diagnostics is a commercial-stage, cancer-prevention medical diagnostics company. Lucid focuses on patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard Esophageal DNA Test is performed on samples collected in a brief noninvasive office procedure with its EsoCheck Esophageal Cell Collection Device, a diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients.
Myosin Therapeutics
Seed Round in 2025
Myosin Therapeutics is a privately-held biopharmaceutical company dedicated to developing innovative medications for central nervous system (CNS) disorders and other significant unmet medical needs. The company focuses on creating novel drugs that target cellular motor proteins, which are essential molecular machines that convert energy into mechanical work within cells. This unique approach enables the potential treatment of various disease states, including cancer. By harnessing the capabilities of these motor proteins, Myosin Therapeutics aims to advance therapeutic options and improve patient outcomes in challenging medical areas.
UCLA Health System
Grant in 2025
Comprised of Ronald Reagan UCLA Medical Center, UCLA Medical Center, Santa Monica; Resnick Neuropsychiatric Hospital at UCLA, Mattel Children's Hospital UCLA, and the UCLA Medical Group with its wide-reaching system of primary-care and specialty-care offices throughout the region, UCLA Health System is among the most comprehensive and advanced healthcare systems in the world.
Neuronoff
Grant in 2025
Neuronoff, a medical device company, is focused on the development of the Injectrode™, a novel injectable metal electrode, which is deployed via a small needle for manufacturing the neuromodulation interface inside the body on a variety of anatomical targets.
IVOS Medical
Grant in 2025
IVOS Medical is an innovative medical device company focused on advancing airway management technology.
Vast Therapeutics
Grant in 2025
Vast Therapeutics develops inhalable treatments for antibiotic-resistant pathogens present in cystic fibrosis and other respiratory disease patients. The company is in the preclinical stage of developing inhalable therapeutics to treat chronic infections common to the cystic fibrosis population.
Arkansas Children's Research Institute
Grant in 2025
Arkansas Children's Research Institute is a not-for-profit organization affiliated with Arkansas Children's, Inc., and is dedicated to advancing pediatric health through research. It operates in conjunction with Arkansas Children's Hospital, the only pediatric medical center in Arkansas and one of the largest in the nation, which spans 29 city blocks and features 370 beds. The hospital employs around 500 physicians and more than 4,400 staff members, focusing on innovative medical research, surgical procedures, and intensive treatments aimed at improving children's health and development. The institute's research efforts contribute to the hospital's reputation for medical breakthroughs and have garnered recognition, including being ranked on the FORTUNE 100 Best Companies to Work For list for three consecutive years.
Feinstein Institute for Medical Research
Grant in 2025
Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.
rhealth
Grant in 2025
Rhealth is a biotechnology company that focuses on delivering advanced health management solutions through an AI-driven platform tailored for hospitals. It aims to enhance the accessibility of analytical and diagnostic information for both physicians and patients. By integrating portable diagnostic and monitoring technologies, Rhealth seeks to transform the way health information is accessed and utilized, ultimately enabling healthcare providers to deliver more timely and effective care.
University of Louisville
Grant in 2025
The University of Louisville is a public research university that offers a wide range of undergraduate and graduate programs across various disciplines. It is particularly known for its contributions to health, engineering, and the humanities. The university actively engages with community partners to enhance its academic and research initiatives, thereby creating a significant impact on education, healthcare, and research industries. Additionally, the University of Louisville School of Dentistry serves as a specialized institute within the university, focusing on dental education and training.
University of Arkansas for Medical Sciences
Grant in 2025
University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.
Scripps Health
Grant in 2024
Scripps Health is a private, nonprofit integrated health system based in San Diego, California, dedicated to delivering high-quality medical care to patients and their families. The organization operates top-ranked hospitals and offers a range of services, including preventive care and wellness screenings tailored to various life stages. Additionally, the Scripps Health Foundation supports these efforts through philanthropic initiatives, ensuring the sustainability of quality patient care in the San Diego area.
Elimu Informatics
Grant in 2024
Elimu Informatics is a developer of cloud-based clinical decision support software designed for healthcare professionals. The company's expertise lies in clinical decision support, semantic normalization, and workflow integration. By focusing on these areas, Elimu Informatics aims to enhance the quality of care, improve patient experiences, and increase usability for healthcare providers. Their solutions allow healthcare professionals to access advanced tools and insights without the burden of additional development costs or lengthy implementation timelines.
BioCircuit Technologies
Grant in 2024
BioCircuit Technologies develops noninvasive electrophysiology devices which monitor, control and repair peripheral nerves. BioCircuit’s products provide clinicians with a practical ability to diagnose health conditions earlier, track the progression of symptoms over time, and select treatments more precisely for individual patients.
BMI OrganBank
Grant in 2024
BMI OrganBank specializes in the development of advanced medical devices and perfusion technology aimed at enhancing the preservation of organs and tissues for transplantation. By collaborating with academic institutions, the company seeks to expand the potential of organ transplantation and improve patient outcomes. Its focus includes innovative solutions that could significantly transform kidney transplantation and other organ preservation methods, ultimately benefiting thousands of patients in need of transplants. The company’s efforts also extend to developing technologies for organ preservation, such as lung ventilators and ex vivo tissue perfusion, which enable healthcare providers to deliver better medical care.
Sparian Biosciences
Grant in 2024
Sparian Biosciences is an early-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies for the central nervous system (CNS). The firm focuses on creating unique medicines that target the brain, utilizing cutting-edge scientific approaches and novel drug discovery techniques. In addition to its core mission, Sparian is also developing a new analgesic aimed at addressing both acute and chronic pain, further emphasizing its commitment to advancing treatments for CNS-related conditions.
Emory University
Grant in 2024
Emory University is a public research university located in Atlanta, Georgia. It offers a range of undergraduate and graduate programs across various fields. The institution generates over $500 million in research funding annually while prioritizing teaching. Emory collaborates with local schools and partners to enhance its educational impact. The university's campus is in the historic Druid Hills area, and its connection to Atlanta shapes it. President James W. Wagner acknowledges the contributions of faculty, staff, students, and alumni to the university's mission and its commitment to improving what is considered good.
Mount Sinai Health System
Grant in 2024
Mount Sinai Health System is an integrated healthcare system based in New York, providing exceptional medical care to local and global communities. Established in 2013 through the merger of Mount Sinai Medical Center and Continuum Health Partners, it encompasses the Icahn School of Medicine and operates seven hospital campuses throughout the New York metropolitan area. The system is recognized for its excellence in research, patient care, and education across various specialties. It features a vast network of over 7,000 primary and specialty care physicians, as well as more than 45 ambulatory practices and 12 minority-owned free-standing ambulatory surgery centers. Mount Sinai is committed to improving healthcare quality and accessibility, focusing on compassionate patient experiences and the development of strong relationships between staff and patients. Additionally, its venture capital arm, Mount Sinai Ventures, invests in healthcare startups, further enhancing its capacity to innovate and respond to the diverse health needs of the populations it serves.
ReShape Medical
Grant in 2024
ReShape Medical Inc. specializes in non-surgical weight loss solutions aimed at individuals with mild to moderate obesity, specifically those with a Body Mass Index (BMI) of 30 to 40. The company offers the ReShape Integrated Dual Balloon System, which consists of two intragastric balloons that are placed in the stomach and filled with saline. This system is intended to assist patients in losing weight when combined with a medically supervised diet and exercise program. The procedure is designed for adults who have not achieved significant weight loss through diet and exercise alone. ReShape Medical also provides other weight management solutions, including the FDA-approved Lap-Band System and the investigational ReShape Vest System, which aim to support patients in their weight loss journeys while minimizing the need for invasive surgical procedures. Founded in 2005 and based in San Clemente, California, ReShape Medical operates as a subsidiary of EnteroMedics Inc.
Novel Microdevices
Grant in 2024
Novel Microdevices, LLC is focused on developing handheld devices for molecular diagnostics, specifically through its product, NOVEL DX. This innovative device utilizes microfluidics technology to analyze raw biological samples directly at the point of care, providing results in just 30 minutes. By enabling healthcare professionals to achieve lab-quality results without the need for a traditional laboratory setting, the device addresses various sectors including clinical diagnostics, biodefense, food safety, forensics, drug discovery, animal care, and agriculture. Founded in 2014 by Andrea Pais, Novel Microdevices is headquartered in Baltimore, Maryland.
Brixton Biosciences
Grant in 2024
Brixton Biosciences is a clinical-stage life sciences company focused on developing innovative therapies for chronic and acute pain management. The company aims to address significant unmet needs in this area, which has traditionally relied on systemic medications. Its flagship product, Neural Ice™, is a drug-free injectable treatment designed to induce reversible inhibition of nerves, offering a non-addictive, locally targeted solution. This therapy provides patients with extended pain relief lasting from thirty to sixty days following a single injection, representing a significant advancement over current pain management methods.
YoungHeartValve
Grant in 2024
Young Heart Valve is a Polymeric, Hyaluronan-Enhanced Transcatheter Aortic Valves which were developed by engineers with inspiration from nature. The future of heart valve intervention is being altered by Young Heart Valve. Animal tissue is no longer required thanks to Young Heart Valve. Hyaluronan is included into the leaflets of Young Heart Valve's RejuvenateTM TAVR device, forming a biomolecular interpenetrated network that has been shown to be resistant to calcification and thrombosis.
ATCC
Grant in 2024
ATCC global biological materials resource and standards organization whose mission focuses on the acquisition, authentication, production, preservation, development, and distribution of standard reference microorganisms, cell lines, and other materials. While maintaining traditional collection materials, ATCC develops high-quality products, standards, and services to support scientific research and breakthroughs that improve the health of global populations.
Caretaker Medical
Grant in 2024
CareTaker is the worlds most innovative patient monitor Using only a simple finger cuff to measure Continuous Beat-by-Beat Blood Pressure (“cNIBP”), Heart Rate, and other physiological parameters enabling safe, secure, and accurate remote patient monitoring via their secure Android App, HIPPA-compliant Cloud Portals, or interfaced with other patient monitoring systems. CareTaker sets a new standard in mobility, simplicity, and cost, enabling continuous realtime monitoring as patients traverse the full continuum of care, within the hospital, during transport, and after discharge.
Pip Care
Grant in 2024
Pip Care is a healthcare company that specializes in enhancing the surgical journey through a personalized platform designed for health systems. The company collaborates with these systems to streamline the perioperative care process, supporting care teams and patients from pre-surgery preparation to post-operative recovery. Pip Care offers a dedicated app that empowers patients by providing certified health coaches who create individualized care plans, including daily tasks and tailored advice, helping them manage appointments and feel prepared for their surgeries. By focusing on the digitization and automation of perioperative workflows, Pip Care aims to improve surgical outcomes for patients while also enhancing the financial performance of healthcare providers.
Arkansas Children's Research Institute
Grant in 2024
Arkansas Children's Research Institute is a not-for-profit organization affiliated with Arkansas Children's, Inc., and is dedicated to advancing pediatric health through research. It operates in conjunction with Arkansas Children's Hospital, the only pediatric medical center in Arkansas and one of the largest in the nation, which spans 29 city blocks and features 370 beds. The hospital employs around 500 physicians and more than 4,400 staff members, focusing on innovative medical research, surgical procedures, and intensive treatments aimed at improving children's health and development. The institute's research efforts contribute to the hospital's reputation for medical breakthroughs and have garnered recognition, including being ranked on the FORTUNE 100 Best Companies to Work For list for three consecutive years.
Teal Health
Grant in 2024
Teal Health is on a mission to empower women when it comes to their health – starting with at-home cervical cancer screenings. We believe that it’s time for women’s health to be designed for women, their preferences, and their experiences. With this in mind, Teal Health is creating the first FDA-approved at-home cervical cancer screening making it simple for a woman to stay current on this life-saving screening from the comfort, convenience, and privacy of her home. Through timely screenings, Teal health plans to eradicate cervical cancer in the US. Teal is backed by passionate and committed investors who share this important vision, including Felicis Ventures, Emerson Collective, Metrodora, and Serena Ventures.
Allyx Therapeutics
Grant in 2024
Allyx Therapeutics, founded in 2018 and based in Durham, Connecticut, is a clinical-stage biotechnology company focused on developing disease-modifying treatments for Alzheimer's Disease. The company’s primary product is an orally bioavailable small molecule that functions as a silent allosteric modulator of mGluR5. This innovative drug aims to reverse neurodegeneration and offers a potential approach to preserve cognitive function in patients with Alzheimer's. By targeting the underlying mechanisms of the disease, Allyx Therapeutics strives to provide effective therapeutic solutions for those affected by neurodegenerative disorders.
CardieX
Grant in 2024
CardieX is a global health technology company that focuses on hypertension, cardiovascular disease, and other vascular health disorders.
University of Michigan
Grant in 2024
The University of Michigan’s programs consistently places high in national rankings. Especially renowned are the Stephen Ross School of Business, the College of Engineering, The Law and Medical Schools, and the Musical Theatre program. There is also a strong film presence in Ann Arbor, with many major motion pictures being shot there and the annual Ann Arbor Film Festival, which brings in filmmakers from all over the world.
Southern California University of Health Sciences
Grant in 2024
Southern California University of Health Sciences has been a leader in educating students to be competent and caring integrative healthcare practitioners for over 100 years. SCU has a history of providing the highest levels of patient care and has gained a reputation for excellence in an evidenceinformed curriculum. SCU is the best place to prepare for a successful, significant, and rewarding career.
Instituto Nacional de Salud Publica
Grant in 2024
The Instituto Nacional de Salud Publica is an academic institution whose central commitment to Mexican society is to provide research results to relevant public health problems in order to prevent and control diseases, as well as to train health professionals who help promote healthy living conditions in the community's various groups. population.
Rosalind Franklin University of Medicine and Science
Grant in 2024
Named after the renowned British scholar who discovered the double helix structure of DNA, the Rosalind Franklin University of Medicine and Science in North Chicago, Illinois, educates students so that they may become health science leaders who advance the industry. The Rosalind Franklin University contains the following schools: * Chicago Medical School * College of Health Professionals * College of Pharmacy * Dr. William M. Scholl College of Podiatric Medicine * School of Graduate and Postdoctoral Studies Academics offered at the university are available in the aforementioned schools. Types of degrees include: * Doctor of Medicine * Doctor of Podiatric Medicine * Nurse Anesthesia * Physical Therapy * Physician’s Assistant As an institution that aims to advance the biomedical and health care sciences, Rosalind offers plenty of research opportunities for students interested in contributing to their evolution. Programs at nearby colleges like Lake Forest College and DePaul University, as well as summer internships at the Chicago Medical School, make it easy for students to get involved. Since medical students need to remain sharp, the university strives to offer an inspiring college life that enriches students professionally, mentally and socially. You can join an organization like the All Staff Assembly or University Faculty Senate to meet new friends, explore shared interests or enhance your professional skills. Each school has its own admissions requirements, although the university seeks students with a sufficient scientific education and leadership skills. For more information on what qualifications you must fulfill to be considered eligible for enrollment, please contact the respective school. Students who file a FAFSA and demonstrate need will be considered for Rosalind Franklin financial aid.
Oklahoma Medical Research Foundation
Grant in 2024
OMRF is the Oklahoma Medical Research Foundation. We are dedicated to fighting Alzheimer’s, heart disease, lupus, MS, cancer and other devastating illnesses.
CytoAgents
Grant in 2024
CytoAgents, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, established in 2018. The company specializes in developing protein-based drugs aimed at treating viral infections, particularly influenza, and addressing life-threatening symptoms associated with Cytokine Release Syndrome (CRS). CRS is an overreaction of the immune system that results in systemic inflammation, often referred to as a cytokine storm. One of its primary products, GP1681, acts as an agonist of a G-protein coupled receptor, targeting the immune response in various medical conditions. CytoAgents focuses on creating treatments for multiple indications with significant unmet medical needs, including those arising from oncology CAR-T cell therapy, COVID-19, and respiratory epidemics, thereby providing healthcare professionals with innovative tools to manage patients experiencing severe immune reactions.
Amissa Health
Grant in 2024
Amissa Health develops digital biomarkers for the early diagnosis, prediction and prevention of Alzheimer’s disease and related dementias.
Resvita Bio
Grant in 2024
Resvita Bio is engaged in the development and manufacturing of engineered probiotics aimed at treating skin-related diseases, including chronic conditions and cancer. The company focuses on creating a versatile skin microbial platform utilizing synthetic biology and metabolic engineering. This innovative approach allows for the continuous delivery of therapies that alleviate inflammation, promote tissue regeneration, and eliminate harmful bacteria. By leveraging this technology, Resvita Bio aims to offer faster and more efficient treatment alternatives for individuals suffering from chronic skin diseases.
Cenna Biosciences
Grant in 2024
Cenna Biosciences focuses on the discovery and development of innovative drugs aimed at preventing and treating Alzheimer's disease. The company utilizes a proprietary technology that targets the underlying cause of the disease, specifically addressing the harmful accumulation of beta-amyloid (Aß) in the brains of affected individuals. Cenna has identified a novel target and is in the process of developing several lead peptide compounds as potential disease-modifying treatments for Alzheimer's.
Lasarrus
Grant in 2024
Lasarrus develops devices for patients with chronic obstructive pulmonary disease. The company was founded in 2013 and is headquartered in Baltimore, Maryland.
Tiziana Life Sciences
Grant in 2024
Tiziana Life Sciences is a clinical-stage biotechnology company based in the United Kingdom, dedicated to the discovery and development of innovative therapies targeting diseases in oncology and immunology. The company's product pipeline features Foralumab, a human anti-CD3 monoclonal antibody aimed at treating various autoimmune and inflammatory conditions, including graft-versus-host disease and multiple sclerosis. Another key asset is Milciclib, an orally bioavailable small molecule that inhibits cyclin-dependent kinases and is currently in phase II clinical trials for epithelial thymic carcinoma and has potential applications in hepatocellular carcinoma. Additionally, Tiziana develops Anti IL-6r, a monoclonal antibody for treating severe respiratory symptoms in hospitalized COVID-19 patients, and StemPrintER, a multi-gene assay designed for patients with specific types of breast cancer. Founded in 2013, Tiziana Life Sciences operates with a focus on advancing transformative therapies for challenging medical conditions.
Nasoni
Grant in 2024
Nasoni, LLC specializes in the design and manufacture of fountain faucets, offering a range of products including centerset and widespread options in polished chrome, brushed nickel, and black nickel finishes. Established in 2015 and headquartered in Suffolk, Virginia, the company focuses on integrating advanced technology into its faucet solutions. Nasoni aims to transform bathrooms into centers of health and wellness, promoting personalized health experiences and enhancing daily self-care routines. The company sells its innovative products through sales representatives and online platforms, emphasizing the importance of maintaining health and wellness with greater independence and efficiency.
TransCode Therapeutics
Grant in 2024
TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on the discovery and development of microRNA (miRNA) therapeutics to treat metastatic diseases. Founded in 2016, the company is dedicated to combating cancer through the targeted eradication of metastatic tumor cells, primarily leveraging its proprietary TTX nanoparticle platform. Its lead therapeutic candidate, TTX-MC138, aims to inhibit microRNA-10b, a key biomarker associated with metastasis, and has shown promising preclinical validation. Additionally, TransCode is advancing a portfolio of innovative RNA therapeutic candidates designed to address the challenges of RNA delivery, thereby expanding therapeutic options for various genetic targets within oncology.
Subtle Medical
Grant in 2024
Subtle Medical, Inc. is a healthcare technology company based in Menlo Park, California, that specializes in developing AI-powered medical imaging software for clinical imaging centers and hospitals. Founded in 2017, the company offers products such as SubtleMR and SubtlePET, both of which are FDA cleared and CE marked. These technologies enhance image quality in magnetic resonance imaging (MRI) and positron emission tomography (PET) exams by reducing noise and increasing sharpness, ultimately improving workflow efficiency while ensuring patient safety. Subtle Medical also features SubtleGAD, a technology recognized by the Radiological Society of North America, which aims to make imaging exams safer. The company employs a vendor-agnostic AI infrastructure that integrates seamlessly with existing scanners, allowing imaging providers to serve more patients effectively by enhancing image acquisition without disrupting their current workflow. Through its innovations, Subtle Medical seeks to improve the quality, value, and accessibility of medical imaging while significantly lowering costs and radiation exposure.
Precision Epigenomics
Grant in 2024
Precision Epigenomics is a molecular diagnostic company that develops molecular diagnostic assays for cancer diagnosis. They provide clinicians with novel tests and services aimed at improving diagnosis, management, and treatment of medical unmet needs using sophisticated bioinformatics and clinical research. Precision Epigenomics is headquartered in Tucson, Arizona and was founded in 2020.
EVOQ Therapeutics
Grant in 2024
Evoq Therapeutics is a company specializing in cancer immunotherapy and the treatment of autoimmune diseases. It employs a proprietary technology platform that features a NanoDisc, designed to deliver disease-specific immune modulators effectively. This innovative approach aims to restore immune tolerance, allowing the body to better manage conditions such as celiac disease, type one diabetes, lupus, pemphigus, Graves' disease, and rheumatoid arthritis. By targeting these diseases through its novel nanodisc-based therapy, Evoq Therapeutics seeks to improve the lives of individuals affected by autoimmune disorders and enhance the overall efficacy of treatment strategies in various pre-clinical models.
Ensysce Biosciences
Grant in 2024
Ensysce Biosciences is a clinical-stage biotech company focused on developing safer prescription drugs through its proprietary technology platforms. The company is creating a new class of tamper-proof opioids designed to prevent both drug abuse and overdoses, addressing the critical issues of addiction and accidental overdose associated with traditional opioid medications. Ensysce utilizes its Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR) platforms to advance the development of these innovative products. The aim is to provide safer treatment options for severe pain while reducing the risk of fatalities linked to opioid misuse, thereby mitigating both human and economic costs. Ensysce's technologies are supported by a comprehensive global intellectual property portfolio covering a wide range of prescription drug compositions.
Unlocked Labs
Grant in 2024
Unlocked Labs specializes in developing innovative probiotics aimed at addressing chronic health conditions by utilizing genetically optimized microbial strains. The company focuses on activating dormant microbial abilities to effectively digest compounds that can lead to health issues. Their first product targets the risk of kidney stones by breaking down stone-forming compounds derived from healthy foods like leafy vegetables. Unlocked Labs employs alternative regulatory pathways to expedite the availability of safe and effective probiotic solutions for consumers. By harnessing the natural detoxifying capabilities of symbiotic microbes, their products aim to reduce acid levels in the body, making them both affordable and accessible to a wide audience.
Penderia Technologies
Grant in 2024
Penderia Technologies is a new medical device company that specializes in creative ways to treat orthopedic ailments.
Marker Therapeutics
Grant in 2024
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company based in Houston, Texas, that focuses on developing and commercializing T cell-based immunotherapies and peptide-based vaccines for hematological malignancies and solid tumors. The company’s MultiTAA technology enhances the effectiveness of non-engineered tumor-specific T cells, enabling them to target multiple tumor-associated antigens simultaneously. This approach aims to prevent immune escape and foster durable immunity. Marker Therapeutics offers autologous T cell therapies for conditions such as lymphoma and multiple myeloma, while also developing allogeneic T cell therapies for acute myeloid leukemia and acute lymphoblastic leukemia. Additionally, the company is advancing peptide-based vaccines, including TPIV100/110 and TPIV200, which are currently in Phase II clinical trials for treating breast and ovarian cancers, respectively.
University of Arkansas for Medical Sciences
Grant in 2024
University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.
Immunovia
Grant in 2024
Immunovia is a diagnostics company focused on the early detection of pancreatic cancer and other complex diseases. Utilizing its proprietary IMMray platform, which is based on antibody microarray analysis, Immunovia develops and commercializes innovative diagnostic tools. The company conducts clinical trials and validation studies to ensure the accuracy and reliability of its tests, collaborating with medical institutions and research centers worldwide. By concentrating on early detection, Immunovia aims to enhance the treatment and management of pancreatic cancer, thereby improving patient survival rates. The technology developed by Immunovia could also facilitate early detection strategies for other cancers and autoimmune diseases in the future.
Cortechs.ai
Grant in 2024
Cortechs.ai develops brain image analysis software aimed at enhancing clinical insight through quantitative imaging. Its innovative solutions cater to neurologists and radiologists, providing them with effective tools for assessing various neurological conditions, including Alzheimer's disease, multiple sclerosis, epilepsy, and traumatic brain injury. The software offers a convenient and cost-effective method to quantify brain structures, facilitating more accurate diagnoses and treatment plans. Used in numerous clinics and research centers globally, Cortechs.ai's technology is instrumental in advancing the field of neurology and improving patient outcomes.
MaMome
Grant in 2024
MaMome is dedicated to advancing women's health, beginning with pregnancy, and extending beyond, by utilizing microbiome coupled with machine learning/AI, we precisely identify expectant mothers at elevated risk of pregnancy complications.
Anebulo Pharmaceuticals
Grant in 2024
Anebulo Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative treatments for individuals experiencing cannabinoid overdose and substance addiction. Its primary product candidate, ANEB-001, is designed to counteract the adverse effects of cannabinoid overdose within one hour of administration. Clinical trials have demonstrated that ANEB-001 is rapidly absorbed and well-tolerated by patients. Additionally, it has been observed to induce weight loss, an effect linked to its action as a central cannabinoid receptor type 1 antagonist. The company aims to address the wide range of symptoms associated with cannabinoid overdose, which can include profound sedation, anxiety, panic, and psychosis with hallucinations.
Arkansas Children's Research Institute
Grant in 2024
Arkansas Children's Research Institute is a not-for-profit organization affiliated with Arkansas Children's, Inc., and is dedicated to advancing pediatric health through research. It operates in conjunction with Arkansas Children's Hospital, the only pediatric medical center in Arkansas and one of the largest in the nation, which spans 29 city blocks and features 370 beds. The hospital employs around 500 physicians and more than 4,400 staff members, focusing on innovative medical research, surgical procedures, and intensive treatments aimed at improving children's health and development. The institute's research efforts contribute to the hospital's reputation for medical breakthroughs and have garnered recognition, including being ranked on the FORTUNE 100 Best Companies to Work For list for three consecutive years.
Weill Cornell Medicine
Grant in 2024
Weill Cornell Medicine operates as a leading medical and graduate school in New York City, focusing on excellence in patient care, scientific discovery, and the education of future physicians. The institution provides a comprehensive range of services, including medical consultancy, healthcare programs, and educational guidance, aimed at healthcare service providers, medical students, and governmental organizations. In addition to its educational mission, Weill Cornell Medicine includes specialized centers such as the Weill Cornell Vein Treatment Center, which offers treatments for various venous conditions and related health issues. The Information Technologies & Services Department plays a crucial role in supporting the institution’s objectives by delivering extensive IT infrastructure and services, enhancing research and clinical operations through innovative technology solutions. This multidisciplinary approach positions Weill Cornell Medicine as a leader in both medicine and technology.
VenoStent
Grant in 2024
VenoStent, Inc. is a clinical-stage tissue engineering company based in Nashville, Tennessee, with an additional office in Houston, Texas. Founded in 2017, it specializes in the development of bioresorbable smart polymers designed to enhance vascular surgery outcomes. The company’s primary product, SelfWrap, is a perivascular wrap that functions as an external stent, providing mechanical support to veins and promoting outward growth. This innovative technology aims to reduce complications at the vein-artery junction in dialysis patients, particularly by minimizing vein collapse and improving the usability of arteriovenous fistulas (AVF). By utilizing a new class of shape-memory polymers that do not require sutures, VenoStent's approach reduces surgery time and lowers the risk of infection, ultimately enhancing the quality and length of life for patients with chronic kidney disease undergoing hemodialysis.
Metabolon
Grant in 2024
Metabolon, Inc. is a health technology company specializing in metabolomics, which focuses on the analysis of metabolites to aid in disease detection and precision medicine. The company develops a range of clinical diagnostic tests, including QUANTOSE IR for early-stage insulin resistance and Meta IMD for identifying metabolites linked to inherited metabolic disorders. Metabolon also offers customizable research services and multiomics solutions, enabling academic and commercial researchers to explore various life sciences areas effectively. The company's technologies address a wide array of health conditions, including cardiovascular issues, diabetes, and cancer, and are utilized across sectors such as biotechnology, pharmaceuticals, and nutrition. Founded in 2000 and headquartered in Morrisville, North Carolina, Metabolon has a global presence, including offices in Munich, London, Madrid, and China, and maintains strategic partnerships with major firms in the pharmaceutical and consumer health industries.
CUNY Graduate School of Public Health and Health Policy(CUNY SPH)
Grant in 2024
CUNY SPH promotes and sustains healthier populations in their city and around the world through education, research, and service in public health. They offer essential insights into public health problems and solutions. They believe collaboration leads to innovative and impactful research, programs, and policies.
Preeclampsia Foundation
Grant in 2024
Preeclampsia Foundation is a nonprofit that focuses on reducing maternal and infant illness and death due to preeclampsia.
Ensysce Biosciences
Grant in 2024
Ensysce Biosciences is a clinical-stage biotech company focused on developing safer prescription drugs through its proprietary technology platforms. The company is creating a new class of tamper-proof opioids designed to prevent both drug abuse and overdoses, addressing the critical issues of addiction and accidental overdose associated with traditional opioid medications. Ensysce utilizes its Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR) platforms to advance the development of these innovative products. The aim is to provide safer treatment options for severe pain while reducing the risk of fatalities linked to opioid misuse, thereby mitigating both human and economic costs. Ensysce's technologies are supported by a comprehensive global intellectual property portfolio covering a wide range of prescription drug compositions.
Matter Bio
Grant in 2024
Matter Bio is a biotechnology company dedicated to preserving genome integrity and enhancing longevity through the preservation of DNA information. The company aims to address the critical issue of information loss in the genome by assembling a team of expert scientists and executives. By focusing on mutation reversal, Matter Bio seeks to empower patients with the potential to improve their health and extend their lifespan. Through its innovative research services, the company strives to advance the understanding and application of genetic preservation techniques.
Nanopath
Grant in 2024
Nanopath Inc. is a molecular diagnostics company focused on enhancing women's health through rapid and precise testing. By utilizing advancements in bioengineering and nanotechnology, the company specializes in the sensitive detection of viral, bacterial, and fungal pathogens without relying on nucleic acid amplification techniques. This innovative approach allows for the delivery of granular and clinically actionable information, thereby improving traditional testing methodologies and enabling healthcare providers to make informed decisions more swiftly.
Phenomix Sciences
Grant in 2024
Phenomix Sciences is a biotechnology company that specializes in biotech, life science, metabolomics, and genomics. It provides healthcare solutions that will enable personalized management of chronic diseases with better efficacy, fewer side effects, and lower costs. The company was founded in 2017 and headquartered in New York, United States.
Arkansas Children's Research Institute
Grant in 2024
Arkansas Children's Research Institute is a not-for-profit organization affiliated with Arkansas Children's, Inc., and is dedicated to advancing pediatric health through research. It operates in conjunction with Arkansas Children's Hospital, the only pediatric medical center in Arkansas and one of the largest in the nation, which spans 29 city blocks and features 370 beds. The hospital employs around 500 physicians and more than 4,400 staff members, focusing on innovative medical research, surgical procedures, and intensive treatments aimed at improving children's health and development. The institute's research efforts contribute to the hospital's reputation for medical breakthroughs and have garnered recognition, including being ranked on the FORTUNE 100 Best Companies to Work For list for three consecutive years.
Annoviant
Grant in 2024
Annoviant is a healthcare company focused on the development of innovative medical devices, specifically tissue-based valve and conduit replacement products. These devices are designed to replace or repair structures that are congenitally absent or underdeveloped. Annoviant's offerings are characterized by their regenerative capabilities and resistance to thrombosis, calcification, and infection. By maintaining essential mechanical properties, these devices aim to enhance clinical outcomes for substitute conduit arteries in infants and children, ultimately reducing the need for repeated surgical interventions.
University of California San Diego
Grant in 2024
The University of California San Diego (UC San Diego) is a public research university that offers a wide range of undergraduate and graduate programs across various disciplines. It emphasizes research, community engagement, and interdisciplinary collaboration, providing students with opportunities to engage in leadership activities and study abroad. The university is known for its School of Medicine, which trains future healthcare professionals through a comprehensive curriculum that builds on students' backgrounds in biological, behavioral, and health sciences. Additionally, UC San Diego hosts multidisciplinary labs focused on human-centered design thinking to address complex systems in automation and healthcare, collaborating with numerous industrial partners. Overall, UC San Diego serves multiple industries, including education, healthcare, and technology, while equipping students with essential resources and guidance for their academic and professional development.
University of Arkansas for Medical Sciences
Grant in 2024
University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.
Selsym
Grant in 2024
Selsym Biotech is a biotechnology company focused on developing innovative therapies aimed at controlling bleeding in trauma and surgical situations. The company's flagship product, Hemostatic Healing Hydrogels (H3), offers a novel solution to address critical challenges in hemorrhage control, particularly in light of ongoing platelet supply shortages and limitations related to shelf life. By providing effective platelet-mimetic therapies, Selsym Biotech seeks to revolutionize the management of uncontrolled bleeding, enhancing outcomes for patients in emergency and surgical settings.
The Feinstein Institutes
Grant in 2024
The Feinstein Institutes is a research services centre.
Cincinnati Children’s
Grant in 2024
Patients and families from across the region and around the world come to Cincinnati Children’s Hospital Medical Center because we are dedicated to improving child health. Other medical providers often turn to us when a child needs a complex surgical procedure or treatment for a rare pediatric disease. We discover new and better ways to treat the conditions that affect children, maintaining our status as one of the world’s foremost centers for pediatric care.
Lamassu Pharma
Grant in 2024
Lamassu Pharma is a biotech startup dedicated to addressing the significant unmet medical need for severe acute pancreatitis. The company is focused on developing a novel small molecule therapy that has shown promising preclinical results in significantly reducing both mortality and morbidity associated with this condition. This therapeutic candidate, developed by leading scientists at Mayo Clinic, aims to improve medical outcomes for patients suffering from acute pancreatitis. Lamassu Pharma is currently advancing the development of this compound through safety testing, preparing for future clinical trials with the ultimate goal of saving lives and enhancing treatment options for those affected by this serious disease.
Springbok Analytics
Grant in 2024
Springbok Analytics offers an AI-powered software platform that transforms MRIs into three-dimensional analyses of muscle to enable true precision. Springbok Analytics' advanced imaging technology identifies and measures each individual muscle, providing data to scientists, physical therapists, athletic trainers, and physicians to evaluate muscle function in relation to performance and injury management. The technology has numerous applications, including injury management, performance enhancement, and the treatment of musculoskeletal conditions.
Phase
Grant in 2024
Phase provides 3D-printing medical devices for microfluidics. Phase’s proprietary platform enables PDMS (Sylgard 184) to be 3D printed at a scale and resolution that was previously unattainable.
Behaivior
Grant in 2024
Behaivior LLC is a digital health company based in Pittsburgh, Pennsylvania, focused on predicting and preventing addiction relapses through innovative technology. Founded in 2017, Behaivior develops a platform that combines wearable devices and machine learning algorithms to monitor key physiological signals such as heart rate and motion. This system, known as Recovery, is designed to support mental health recovery and wellness by delivering timely interventions based on real-time data. By utilizing a software-as-a-service (SaaS) model, Behaivior empowers individuals to maintain their recovery process while enabling care providers to better assist their clients. The integration of AI and behavioral health technology allows Behaivior to recognize patterns in human behavior, ultimately aiming to enhance mental well-being and reduce the incidence of crises, including relapse.
Maxim Biotech
Grant in 2024
Maxim Biotech provides vitro diagnostic testing development and testing solutions.
BetterAge
Grant in 2024
BetterAge was founded on a vision that all adults, regardless of age, can live well and age well. By building a network of innovators, experts and practitioners across aging services, health, and technology, we are harnessing the best minds to improve the health and well-being of millions of older adults. Our platform of personalized, objective, expert content is designed with - and exclusively for - older adults, and supports thriving communities of active, healthy older adults.
Perspective Therapeutics
Grant in 2024
Perspective Therapeutics is a medical technology and radiopharmaceutical company focused on innovative cancer treatment solutions. The company employs a proprietary technology that uses the alpha-emitting isotope 212Pb combined with specialized targeting peptides to deliver targeted radiation directly to cancer cells. This approach aims to enhance the effectiveness of treatments while minimizing side effects, reflecting the company's commitment to personalized and precise medicine in addressing patients' medical needs.
AcuraStem
Grant in 2024
AcuraStem Inc is a biotechnology company, founded in 2016 and based in Monrovia, California, that focuses on developing a precision medicine platform aimed at addressing Amyotrophic Lateral Sclerosis (ALS). The company utilizes complex cellular models derived from ALS patients to evaluate disease progression and test existing FDA-approved therapeutics and their combinations. By employing advanced cellular reprogramming and artificial intelligence technologies, AcuraStem seeks to transform the standard of care for neurodegenerative diseases, enabling drug discovery companies to assess their therapeutic candidates more effectively. The team comprises experts, including PhDs, professors, and experienced professionals from the pharmaceutical industry, all dedicated to finding innovative treatments for this challenging health issue.
University of Arkansas for Medical Sciences
Grant in 2024
University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.
InVivo Biosystems
Grant in 2024
InVivo Biosystems specializes in utilizing non-mammalian model organisms for biological and biomedical research. The company has developed a proprietary transgenic platform that allows for the genetic modification of simple microscopic animals, such as C. elegans and zebrafish, to serve as human proxies in disease research and drug discovery. This innovative approach provides researchers with valuable insights into genetic mutations and human health. By offering custom genome-edited models, InVivo Biosystems supports pharmaceutical, nutraceutical, and biotechnology companies, as well as academic institutions, in accelerating their research and drug development initiatives. The company aims to make research more affordable and accessible, ultimately contributing to the exploration of treatments for significant health challenges, including Alzheimer's disease, epilepsy, and cancer.
RNAConnect
Grant in 2024
RNAConnect provides enzymatic tools for visualizing and manipulating RNA.
Midwest Bioprocessing Center
Grant in 2023
Midwest Bioprocessing Center is a pioneer in glycochemical bioprocess technology.
University of Arkansas for Medical Sciences
Grant in 2023
University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.
Orlance
Grant in 2023
Orlance provides more effective therapeutic and preventive vaccines for a wide spectrum of viral targets.
Amydis
Grant in 2023
Amydis is a privately-held pharmaceutical company focused on developing innovative diagnostic solutions for diseases associated with amyloid proteins. The company aims to create a universal, non-invasive diagnostic tool that is faster, more accessible, and affordable than existing tests for conditions with unmet clinical needs. Amydis has developed a platform of novel compounds that fluoresce upon binding to amyloid proteins, facilitating the diagnosis of various diseases. Its primary focus is on the early detection of Alzheimer's disease, but it also explores potential applications for detecting Parkinson’s disease, Creutzfeldt-Jakob disease, Pre-eclampsia, TTR Amyloidosis, and Cerebral Amyloid Angiopathy. By providing diagnostic capabilities for amyloid-associated diseases, Amydis empowers patients and healthcare professionals to make informed decisions about health risks.
Virtuoso Surgical
Grant in 2023
Virtuoso Surgical focuses on developing robotic tools specifically for minimally invasive endoscopic surgery. The company's surgical system features needle-sized robotic arms that allow surgeons to navigate and operate in hard-to-reach areas of the body, addressing limitations posed by traditional endoscopes. By providing dexterous and accurate instruments, Virtuoso Surgical aims to enhance surgical precision and improve patient outcomes while also offering a cost-effective solution for healthcare providers.
The Stark Neurosciences Research Institute
Grant in 2023
The Stark Neurosciences Research Institute is dedicated to improving outcomes for persons suffering from disorders of the nervous system.
Hillhurst Biopharmaceuticals
Grant in 2023
Hillhurst has created technology that allows low-dose carbon monoxide to be used therapeutically (CO). Their medicines that arise target a protective cellular metabolic system of heme oxygenase, that is hypothesized to reduce inflammatory processes, prevent cell death, and stop hemoglobin polymerization in sickle cell disease. Despite overwhelming evidence of CO's potential efficacy as a therapy, it has not been commercially feasible to dose carbon monoxide. The methods of administration that have been tried, such as breathing CO and CO bound to a carrier like co releasing molecules/CORMS and CO prodrugs, have significant drawbacks. These hurdles for inhaled co include caregiver inhalation exposure due to the need for pressurized co gas cylinders and imprecise dosing.
Endomimetics
Grant in 2023
Endomimetics is focused on developing advanced bio-nanometric coating technology aimed at enhancing medical care for patients with kidney diseases. The company's innovative stent coating technology is designed to closely mimic human tissue, which helps to minimize the need for additional surgeries and improves the longevity of the devices. By reducing complications associated with the implantation of foreign materials, Endomimetics' technology aims to provide better outcomes for patients, ultimately improving their overall quality of care in the management of kidney-related health issues.
The New York Society for the Prevention of Cruelty to Children
Grant in 2023
The New York Society for the Prevention of Cruelty to Children is a charity that offers counseling, legal, and educational services.
Soterya
Seed Round in 2023
On average, we spend a third of our lives in bed. Our self-positioning bed; the Korus™, combined with our AI-driven software, is designed to provide precise sleep therapies improving lifestyle and medical care that benefits sleep wellness and faster recovery at home.
Rivanna
Grant in 2023
Rivanna Medical, LLC is a medical technology company based in Charlottesville, Virginia, founded in 2010. The company focuses on developing and commercializing innovative ultrasound-based systems aimed at enhancing the application of spinal and epidural anesthesia through advanced 3D navigation of the lumbar spine. Its flagship product, Accuro, not only facilitates precise anesthesia delivery but also supports various diagnostic imaging needs, including musculoskeletal and abdominal anatomies. Rivanna Medical is committed to improving patient outcomes and lowering healthcare costs while minimizing patient exposure to radiation commonly associated with X-ray-based imaging techniques.
Center for HIV Identification, Prevention, and Treatment Services
Grant in 2023
Center for HIV Identification, Prevention, and Treatment Services is a research organisation that conducts HIV research. They offers customer support through email and phone contact.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.